U.S. States Navigate Psychedelics Reforms Amidst Legalization Efforts

2.7 min readPublished On: November 6th, 2023By

As the United States continues to explore the boundaries of drug policy reform, numerous state legislatures and advocacy groups are engaging in a concerted effort to redefine the legal status of psychedelics. From decriminalization and legalization to the establishment of new research agencies, the landscape of psychedelics law is shifting, albeit with nuanced public support.

California Adjusts Course on Psychedelics Research Initiative

In California, the journey towards legal reform encountered a setback when the TREAT (Therapeutic Research and Education Act) initiative, intended to fund psychedelics research through a state agency, was withdrawn from the 2024 ballot. Facing a potential 60% opposition from voters, the campaign is recalibrating its strategy towards broader mental health solutions with the rebranded TREAT Humanity initiative.

Simultaneously, the Psychedelic Wellness and Healing Initiative has been filed with the goal of legalizing the use, possession, and cultivation of psychedelics for various purposes, provided there is a doctor’s recommendation. As the initiative moves through a public comment period, advocates prepare to collect signatures to secure its place on the 2024 ballot.

A separate initiative, spearheaded by Decriminalize California, aims to legalize psilocybin for adult and therapeutic use and is currently in the process of gathering the necessary support.

Wisconsin and Kratom Legislation

Wisconsin is making strides with bills SB 445 and AB 393 that seek to define and legalize kratom products for consumption, while also aiming to remove the substance from the state-controlled substances list. These bills are currently under review in their respective committees.

Massachusetts Pushes for Psychedelics Legalization

In Massachusetts, the MA for Mental Health Options campaign has reportedly gathered sufficient signatures to compel the state legislature to consider its psychedelics legalization initiative. The proposal encompasses legalization for adult use and aims to create a regulated framework for access to these substances. Legislative efforts are also in motion with bill S 1263, which seeks to regulate the safe use of psilocybin and is presently in committee review.

Illinois Explores Psilocybin Regulation

The Illinois Compassionate Use and Research of Entheogens (CURE) Act has been introduced to facilitate the licensing for psilocybin products and services. The bill, which outlines the creation of an advisory board and related funds, is currently under review by the Assignments Committee.

Pennsylvania Aligns with Federal Scheduling

Pennsylvania’s Senate Bill 959 looks to amend state law to adhere strictly to federal scheduling of controlled substances. The bill has successfully passed the Senate and is now with the House Judiciary committee for consideration.

Federal Agencies and Presidential Candidate Weigh In

On the federal front, the FDA has issued warnings regarding ketamine misuse, whereas the DEA has proposed an increase in production quotas for psychedelics and cannabis for research. Presidential candidate Marianne Williamson has called for a healthcare system inclusive of psychedelic treatments for mental health, reflecting a growing conversation about the role of these substances in therapy.

Local Movements Toward Decriminalization

At the local level, cities in Maine and California have enacted policies decriminalizing the possession and use of entheogens, signaling a growing trend toward the acceptance of these substances at the community level.

In conclusion, while the march towards psychedelics reform continues across the United States, the path remains complex and varied, with public opinion, legislative challenges, and advocacy efforts shaping the future of psychedelics law and research.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!